By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EpiGenesis Pharmaceuticals, Inc. 

7 Clark Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-409-6080 Fax: 609-409-6126

EpiGenesis Pharmaceuticals, Inc. is privately held and located in Cranbury, NJ. EpiGenesis uniquely combines gene identification and validation technology based upon antisense oligonucleotides with advanced proprietary animal models of human disease to identify new therapeutics with the potential to revolutionize the treatment of respiratory disease. The antisense molecules used for target validation can be directly employed as therapeutics because of the unique properties of the lung. The company also leverages antisense information to enable a complementary small molecule therapeutics program.

Target Validation Technology-EpiGenesis' Antisense Oligonucleotide approach is the only proven technology for target validation in the respiratory tract and is specifically tailored to evaluate targets for asthma, allergic rhinitis, chronic obstructive pulmonary disease and lung cancer.

Respirable Antisense Oligonucleotide Platform Technology-EpiGenesis can harness the antisense probes used for target validation directly as therapeutics because of the unique properties of the lung. EpiGenesis has a library of Multi-target Respirable Antisense Oligonucleotides whose individual members are each capable to inhibiting multiple disease mediators.

Dual Platform for Drug Discovery-EpiGenesis applies the results of its Respirable Antisense Oligonucleotide screening program to the development of both Respirable Antisense Oligonucleotides and small molecular weight organic molecules.

Proprietary Models of Respiratory Disease-The Company's proprietary models of human asthma represents an important advance in the accuracy of modeling human asthma.

Pharmacogenomics Technology-EpiGenesis is the first company to exploit pharmacogenomics in the respiratory tract by incorporating into its development portfolio its Rainbow ABC™, a test used in the differential diagnosis of asthma.

Drugs in Development-EpiGenesis' two most advanced respiratory drug candidates are:
  • IPE-2010 (Durason™), is a Respirable Antisense Oligonucleotide having the potential to be the first once per week and first ripple action preventative asthma drug; EPI-2010 is scheduled for clinical trials 4Q00.
  • EPI-12323 (Naturasone™), is a product of the Company's parallel Small Molecule Discovery Program; EPI-12323 is scheduled for clinical rials 1Q01.

Last Updated 10-19-01

Key Statistics

Ownership: Private

Web Site: EpiGenesis Pharmaceuticals, Inc.
Employees: 42


Company News
Currently No News Articles